Longeveron Inc. (LGVN): CMO Dr. Nataliya Agafonova resigned

LGVN · Nasdaq · Pharmaceutical Preparations · <br>Emerging growth company · FL · Form 8-K filed 2026-10-14

Dr. Nataliya Agafonova resigned as Chief Medical Officer, effective October 14, 2026.

Open seatNo successor namedEffective within 30 days

Events in this filing

1 event: Departure (CMO).

Names, stated reasons, successor status, compensation terms and the evidence quotes are shown to subscribers. See plans

Item 5.02 as filed

Item 5.02. Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) On October 7, 2026, Dr. Nataliya Agafonova informed management
of Longeveron Inc. of her decision to step down as Chief Medical Officer, to become effective October 14, 2026.
1

Source filing on EDGAR →